J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Radwanski, E
Right arrow Articles by Zampaglione, N
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Radwanski, E
Right arrow Articles by Zampaglione, N
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Articles

Pharmacokinetics of interferon alpha-2b in healthy volunteers

E Radwanski, G Perentesis, S Jacobs, E Oden, M Affrime, S Symchowicz, and N Zampaglione

In a three-way crossover design, 12 healthy male volunteers received 5 X 10(6) IU/m2 body surface area interferon alpha-2b(IFN alpha-2b) by intravenous (IV) infusion over 30 minutes, intramuscular (IM) injections, and subcutaneous (SC) injections. Blood and urine samples were collected at specified times, and analysis of IFN alpha-2b concentrations was performed by immunoradiometric assay. "Flulike" symptoms were the most frequently reported adverse experiences and were independent of the route of administration. After a 30-minute IV infusion, IFN alpha-2b disappeared rapidly from serum, with distribution and elimination phase half-lives of 0.1 hour and 1.7 hours, respectively. Interferon alpha-2b was absorbed slowly after IM and SC administration, with similar absorption half-lives of 5.8 and 5.5 hours, respectively. The observed maximal concentrations after IM and SC administration were 42.1 IU/mL at six hours and 45.8 IU/mL at eight hours, respectively. Interferon alpha-2b was eliminated with half-lives of 2.2 hours after IM administration and 2.9 hours after SC administration. The areas under the serum concentration-time curves for the SC and IM doses were higher than those obtained for the IV infusion. Measurable amounts of IFN alpha-2b were not found in urine regardless of the route of administration.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 BloodHome page
R. Benjamin, A. Khwaja, N. Singh, J. McIntosh, A. Meager, M. Wadhwa, C. Streck, C. Ng, A. M. Davidoff, and A. C. Nathwani
Continuous delivery of human type I interferons ({alpha}/{beta}) has significant activity against acute myeloid leukemia cells in vitro and in a xenograft model
Blood, February 1, 2007; 109(3): 1244 - 1247.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
L. J. Hofland, W. W. de Herder, M. Waaijers, J. Zuijderwijk, P. Uitterlinden, P. M. van Koetsveld, and S. W. J. Lamberts
Interferon-{alpha}-2a Is a Potent Inhibitor of Hormone Secretion by Cultured Human Pituitary Adenomas
J. Clin. Endocrinol. Metab., September 1, 1999; 84(9): 3336 - 3343.
[Abstract] [Full Text]

Home page
 Proc. Natl. Acad. Sci. USAHome page
H. M. Horton, D. Anderson, P. Hernandez, K. M. Barnhart, J. A. Norman, and S. E. Parker
A gene therapy for cancer using intramuscular injection of plasmid DNA encoding interferon alpha
PNAS, February 16, 1999; 96(4): 1553 - 1558.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1987 by the American College of Clinical Pharmacology